# US 2021/0332149 A1 · Anti-human tlr7 antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332149 A1
- Document ID: US20210332149A1
- Status: Published application
- Kind: A1
- Application number: 17/366,820
- Filed: 2021-07-02
- Published: 2021-10-28
- Earliest claimed: 2018-05-31
- Assignees: Daiichi Sankyo Company, Limited; The University of Tokyo
- Applicants: Daiichi Sankyo Company, Limited; The University of Tokyo
- Inventors: Kensuke Miyake; Yusuke Murakami; Yuji Motoi; Atsuo Kanno; Toshiyuki Shimizu; Umeharu Ohto; Takaichi Shimozato; Atsushi Manno; Takashi Kagari; Jun Ishiguro; Kensuke Nakamura; Takashi Isobe
- Web page: https://patentgrep.com/patent/US20210332149A1

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61K 39/39541: {against normal tissues, cells}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C12N 5/10: Cells modified by introduction of foreign genetic material
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.

## Claims

### Claim 1

A polynucleotide comprising a polynucleotide sequence encoding an antibody or an antigen-binding fragment of the antibody, wherein the antibody or an antigen-binding fragment of the antibody having the properties of:
(a) specifically binding to human TLR7 or monkey TLR7 and not binding to mouse TLR7 or rat TLR7;
(b) inhibiting a function of human TLR7 or monkey TLR7; and
(c) comprising CDRH1 consisting of the amino acid sequence set forth in SEQ ID NO: 17, CDRH2 consisting of the amino acid sequence set forth in SEQ ID NO: 18 and CDRH3 consisting of the amino acid sequence set forth in SEQ ID NO: 19, as complementarity determining regions in the heavy chain, and CDRL1 consisting of the amino acid sequence set forth in SEQ ID NO: 20, CDRL2 consisting of the amino acid sequence set forth in SEQ ID NO: 21 and CDRL3 consisting of the amino acid sequence set forth in SEQ ID NO: 22, as complementarity determining regions in the light chain.

### Claim 2 (depends on 1)

The polynucleotide comprising a polynucleotide sequence encoding the antibody or the antigen-binding fragment of the antibody according to claim 1, wherein the human TLR7 is a molecule consisting of the amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 4, the monkey TLR7 is a molecule consisting of the amino acid sequence set forth in SEQ ID NO: 85, the mouse TLR7 is a molecule consisting of the amino acid sequence set forth in SEQ ID NO: 83, or the rat TLR7 is a molecule consisting of the amino acid sequence set forth in SEQ ID NO: 84.

### Claim 3 (depends on 1)

The polynucleotide comprising a polynucleotide sequence encoding the antibody or the antigen-binding fragment of the antibody according to claim 1, wherein the antibody or the antigen-binding fragment of the antibody comprising: a heavy-chain variable region consisting of the amino acid sequence set forth in SEQ ID NO: 5 and a light-chain variable region consisting of the amino acid sequence set forth in SEQ ID NO: 11.

### Claim 4 (depends on 1)

The polynucleotide comprising a polynucleotide sequence encoding the antibody or the antigen-binding fragment of the antibody according to claim 1, wherein a constant region is a human-derived constant region.

### Claim 5 (depends on 4)

The polynucleotide comprising a polynucleotide sequence encoding the antibody or the antigen-binding fragment of the antibody according to claim 4, comprising: a heavy chain consisting of an amino acid sequence at positions 20 to 465 in the amino acid sequence set forth in SEQ ID NO: 35 and a light chain consisting of an amino acid sequence at positions 21 to 233 in the amino acid sequence set forth in SEQ ID NO: 36.

### Claim 6 (depends on 1)

The polynucleotide comprising a polynucleotide sequence encoding the antibody or the antigen-binding fragment of the antibody according to claim 1, wherein the antibody or the antigen-binding fragment of the antibody is humanized.

### Claim 7 (depends on 6)

The polynucleotide comprising a polynucleotide sequence encoding the antibody or the antigen-binding fragment of the antibody according to claim 6, comprising:
(a) a heavy-chain variable region consisting of the amino acid sequence set forth in SEQ ID NO: 41 and a light-chain variable region consisting of the amino acid sequence set forth in SEQ ID NO: 43;
(b) a heavy-chain variable region consisting of the amino acid sequence set forth in SEQ ID NO: 41 and a light-chain variable region consisting of the amino acid sequence set forth in SEQ ID NO: 44;
(c) a heavy-chain variable region consisting of the amino acid sequence set forth in SEQ ID NO: 42 and a light-chain variable region consisting of the amino acid sequence set forth in SEQ ID NO: 43; or
(d) a heavy-chain variable region consisting of the amino acid sequence set forth in SEQ ID NO: 42 and a light-chain variable region consisting of the amino acid sequence set forth in SEQ ID NO: 44.

### Claim 8 (depends on 7)

The polynucleotide comprising a polynucleotide sequence encoding the antibody or the antigen-binding fragment of the antibody according to claim 7, comprising a heavy-chain variable region consisting of the amino acid sequence set forth in SEQ ID NO: 42 and a light-chain variable region consisting of the amino acid sequence set forth in SEQ ID NO: 44.

### Claim 9 (depends on 7)

The polynucleotide comprising a polynucleotide sequence encoding the antibody or the antigen-binding fragment of the antibody according to claim 7, comprising:
(a) a heavy chain consisting of an amino acid sequence at positions 20 to 465 in the amino acid sequence set forth in SEQ ID NO: 45 and a light chain consisting of an amino acid sequence at positions 21 to 233 in the amino acid sequence set forth in SEQ ID NO: 48;
(b) a heavy chain consisting of an amino acid sequence at positions 20 to 465 in the amino acid sequence set forth in SEQ ID NO: 45 and a light chain consisting of an amino acid sequence at positions 21 to 233 in the amino acid sequence set forth in SEQ ID NO: 49;
(c) a heavy chain consisting of an amino acid sequence at positions 20 to 465 in the amino acid sequence set forth in SEQ ID NO: 46 and a light chain consisting of an amino acid sequence at positions 21 to 233 in the amino acid sequence set forth in SEQ ID NO: 48;
(d) a heavy chain consisting of an amino acid sequence at positions 20 to 465 in the amino acid sequence set forth in SEQ ID NO: 46 and a light chain consisting of an amino acid sequence at positions 21 to 233 in the amino acid sequence set forth in SEQ ID NO: 49;
(e) a heavy chain consisting of an amino acid sequence at positions 20 to 462 in the amino acid sequence set forth in SEQ ID NO: 47 and a light chain consisting of an amino acid sequence at positions 21 to 233 in the amino acid sequence set forth in SEQ ID NO: 48; or
(f) a heavy chain consisting of an amino acid sequence at positions 20 to 462 in the amino acid sequence set forth in SEQ ID NO: 47 and a light chain consisting of an amino acid sequence at positions 21 to 233 in the amino acid sequence set forth in SEQ ID NO: 49.

### Claim 10 (depends on 9)

The polynucleotide comprising a polynucleotide sequence encoding the antibody or the antigen-binding fragment of the antibody according to claim 9, comprising a heavy chain consisting of an amino acid sequence at positions 20 to 465 in the amino acid sequence set forth in SEQ ID NO: 46 and a light chain consisting of an amino acid sequence at positions 21 to 233 in the amino acid sequence set forth in SEQ ID NO: 49.

### Claim 11 (depends on 1)

The polynucleotide comprising a polynucleotide sequence encoding the antibody or the antigen-binding fragment of the antibody according to claim 1, wherein the antigen-binding fragment is selected from the group consisting of Fab, F(ab)2, Fab′ and Fv.

### Claim 12

A polynucleotide comprising a polynucleotide sequence encoding an antibody or an antigen-binding fragment of the antibody, wherein the antibody or an antigen-binding fragment of the antibody having the properties of:
(a) specifically binding to human TLR7,
(b) inhibiting a function of human TLR7, and
(c) comprising CDRH1 consisting of the amino acid sequence set forth in SEQ ID NO: 17, CDRH2 consisting of the amino acid sequence set forth in SEQ ID NO: 18 and CDRH3 consisting of the amino acid sequence set forth in SEQ ID NO: 19, as complementarity determining regions in the heavy chain, and CDRL1 consisting of the amino acid sequence set forth in SEQ ID NO: 20, CDRL2 consisting of the amino acid sequence set forth in SEQ ID NO: 21 and CDRL3 consisting of the amino acid sequence set forth in SEQ ID NO: 22, as complementarity determining regions in the light chain.

### Claim 13 (depends on 12)

The polynucleotide comprising the polynucleotide sequence encoding the antibody or the antigen-binding fragment of the antibody according to claim 12, wherein the antibody or the antigen-binding fragment of the antibody comprises a heavy-chain variable region consisting of the amino acid sequence set forth in SEQ ID NO: 5 and a light-chain variable region consisting of the amino acid sequence set forth in SEQ ID NO: 11.

### Claim 14 (depends on 12)

The polynucleotide comprising the polynucleotide sequence encoding the antibody or the antigen-binding fragment of the antibody according to claim 12, wherein a constant region is a human-derived constant region.

### Claim 15 (depends on 14)

The polynucleotide comprising the polynucleotide sequence encoding the antibody or the antigen-binding fragment of the antibody according to claim 14, wherein the antibody or the antigen-binding fragment of the antibody comprises a heavy chain consisting of an amino acid sequence at positions 20 to 465 in the amino acid sequence set forth in SEQ ID NO: 35 and a light chain consisting of an amino acid sequence at positions 21 to 233 in the amino acid sequence set forth in SEQ ID NO: 36.

### Claim 16 (depends on 12)

The polynucleotide comprising the polynucleotide sequence encoding the antibody or the antigen-binding fragment of the antibody according to claim 12, wherein the antibody or the antigen-binding fragment of the antibody is humanized.

### Claim 17 (depends on 16)

The polynucleotide comprising the polynucleotide sequence encoding the antibody or the antigen-binding fragment of the antibody according to claim 16, wherein the antibody or the antigen-binding fragment of the antibody comprises:
(a) a heavy-chain variable region consisting of the amino acid sequence set forth in SEQ ID NO: 41 and a light-chain variable region consisting of the amino acid sequence set forth in SEQ ID NO: 43;
(b) a heavy-chain variable region consisting of the amino acid sequence set forth in SEQ ID NO: 41 and a light-chain variable region consisting of the amino acid sequence set forth in SEQ ID NO: 44;
(c) a heavy-chain variable region consisting of the amino acid sequence set forth in SEQ ID NO: 42 and a light-chain variable region consisting of the amino acid sequence set forth in SEQ ID NO: 43; or
(d) a heavy-chain variable region consisting of the amino acid sequence set forth in SEQ ID NO: 42 and a light-chain variable region consisting of the amino acid sequence set forth in SEQ ID NO: 44.

### Claim 18 (depends on 17)

The polynucleotide comprising the polynucleotide sequence encoding the antibody or the antigen-binding fragment of the antibody according to claim 17, wherein the antibody or the antigen-binding fragment of the antibody comprises a heavy-chain variable region consisting of the amino acid sequence set forth in SEQ ID NO: 42 and a light-chain variable region consisting of the amino acid sequence set forth in SEQ ID NO: 44.

### Claim 19 (depends on 17)

The polynucleotide comprising the polynucleotide sequence encoding the antibody or the antigen-binding fragment of the antibody according to claim 17, wherein the antibody or the antigen-binding fragment of the antibody comprises:
(a) a heavy chain consisting of an amino acid sequence at positions 20 to 465 in the amino acid sequence set forth in SEQ ID NO: 45 and a light chain consisting of an amino acid sequence at positions 21 to 233 in the amino acid sequence set forth in SEQ ID NO: 48;
(b) a heavy chain consisting of an amino acid sequence at positions 20 to 465 in the amino acid sequence set forth in SEQ ID NO: 45 and a light chain consisting of an amino acid sequence at positions 21 to 233 in the amino acid sequence set forth in SEQ ID NO: 49;
(c) a heavy chain consisting of an amino acid sequence at positions 20 to 465 in the amino acid sequence set forth in SEQ ID NO: 46 and a light chain consisting of an amino acid sequence at positions 21 to 233 in the amino acid sequence set forth in SEQ ID NO: 48;
(d) a heavy chain consisting of an amino acid sequence at positions 20 to 465 in the amino acid sequence set forth in SEQ ID NO: 46 and a light chain consisting of an amino acid sequence at positions 21 to 233 in the amino acid sequence set forth in SEQ ID NO: 49;
(e) a heavy chain consisting of an amino acid sequence at positions 20 to 462 in the amino acid sequence set forth in SEQ ID NO: 47 and a light chain consisting of an amino acid sequence at positions 21 to 233 in the amino acid sequence set forth in SEQ ID NO: 48; or
(f) a heavy chain consisting of an amino acid sequence at positions 20 to 462 in the amino acid sequence set forth in SEQ ID NO: 47 and a light chain consisting of an amino acid sequence at positions 21 to 233 in the amino acid sequence set forth in SEQ ID NO: 49.

### Claim 20

A polynucleotide comprising a polynucleotide sequence encoding an antibody or an antigen-binding fragment of the antibody, wherein the antibody or the antigen-binding fragment of the antibody comprises a heavy chain consisting of an amino acid sequence at positions 20 to 465 in the amino acid sequence set forth in SEQ ID NO: 46 and a light chain consisting of an amino acid sequence at positions 21 to 233 in the amino acid sequence set forth in SEQ ID NO: 49.

### Claim 21 (depends on 12)

The polynucleotide comprising a polynucleotide sequence encoding an antibody or an antigen-binding fragment of the antibody according to claim 12, wherein the antigen-binding fragment of the antibody is selected from the group consisting of Fab, F(ab)2, Fab′ and Fv.

### Claim 22 (depends on 12)

The polynucleotide comprising a polynucleotide sequence encoding an antibody or an antigen-binding fragment of the antibody according to claim 12, comprising:
a polynucleotide sequence selected from the group consisting of:
(a) a polynucleotide sequence encoding the heavy-chain variable region set forth in SEQ ID NO: 77;
(b) a polynucleotide sequence encoding the heavy-chain variable region set forth in SEQ ID NO: 78; and
(c) a polynucleotide sequence of a polynucleotide which hybridizes with a polynucleotide consisting of a polynucleotide sequence complementary to the polynucleotide sequence (a) or (b) under stringent conditions; and
a polynucleotide sequence selected from the group consisting of:
(d) a polynucleotide sequence encoding the light-chain variable region set forth in SEQ ID NO: 79;
(e) a polynucleotide sequence encoding the light-chain variable region set forth in SEQ ID NO: 80; and
(f) a polynucleotide sequence of a polynucleotide which hybridizes with a polynucleotide consisting of a polynucleotide sequence complementary to the polynucleotide sequence (d) or (e) under stringent conditions.

### Claim 23 (depends on 22)

The polynucleotide according to claim 22, comprising:
(a) a polynucleotide sequence encoding the heavy-chain variable region set forth in SEQ ID NO: 77 and a polynucleotide sequence encoding the light-chain variable region set forth in SEQ ID NO: 79;
(b) a polynucleotide sequence encoding the heavy-chain variable region set forth in SEQ ID NO: 77 and a polynucleotide sequence encoding the light-chain variable region set forth in SEQ ID NO: 80;
(c) a polynucleotide sequence encoding the heavy-chain variable region set forth in SEQ ID NO: 78 and a polynucleotide sequence encoding the light-chain variable region set forth in SEQ ID NO: 79; or
(d) a polynucleotide sequence encoding the heavy-chain variable region set forth in SEQ ID NO: 78 and a polynucleotide sequence encoding the light-chain variable region set forth in SEQ ID NO: 80.

### Claim 24 (depends on 1)

An expression vector comprising the polynucleotide according to claim 1.

### Claim 25 (depends on 24)

A host cell transformed with the expression vector according to claim 24.

### Claim 26 (depends on 25)

The host cell according to claim 25, wherein the host cell is a eukaryotic cell.

### Claim 27 (depends on 25)

A method for producing an antibody or an antigen-binding fragment of the antibody, comprising the steps of:
culturing the host cell according to claim 25; and
collecting the antibody or the fragment of interest from the culture obtained in the above step.

### Claim 28 (depends on 12)

An expression vector comprising the polynucleotide according to claim 12.

### Claim 29 (depends on 28)

A host cell transformed with the expression vector according to claim 28.

### Claim 30 (depends on 29)

The host cell according to claim 29, wherein the host cell is a eukaryotic cell.

### Claim 31 (depends on 29)

A method for producing an antibody or an antigen-binding fragment of the antibody, comprising the steps of:
culturing the host cell according to claim 29; and
collecting the antibody or the fragment of interest from the culture obtained in the above step.

### Claim 32 (depends on 20)

An expression vector comprising the polynucleotide according to claim 20.

### Claim 33 (depends on 32)

A host cell transformed with the expression vector according to claim 32.

### Claim 34 (depends on 33)

The host cell according to claim 33, wherein the host cell is a eukaryotic cell.

### Claim 35 (depends on 33)

A method for producing an antibody or an antigen-binding fragment of the antibody, comprising the steps of:
culturing the host cell according to claim 33; and
collecting the antibody or the fragment of interest from the culture obtained in the above step.

### Claim 36 (depends on 22)

An expression vector comprising the polynucleotide according to claim 22.

### Claim 37 (depends on 36)

A host cell transformed with the expression vector according to claim 36.

### Claim 38 (depends on 37)

The host cell according to claim 37, wherein the host cell is a eukaryotic cell.

### Claim 39 (depends on 37)

A method for producing an antibody or an antigen-binding fragment of the antibody, comprising the steps of:
culturing the host cell according to claim 37; and
collecting the antibody or the fragment of interest from the culture obtained in the above step.
